KBP Biosciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, KBP Biosciences sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

KBP Biosciences: 12 sponsored US clinical trials, none currently recruiting.

KBP Biosciences sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 1 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Subjects, with 1 trials.

Top-decile sponsor footprint

KBP Biosciences ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

11 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED Phase 1

Study of KBP-7072 in Healthy Male and Female Subjects

NCT05507463
TERMINATED Phase 3

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

NCT04968184
COMPLETED Phase 1

Mass Balance Study of KBP-5074 in Healthy Male Subjects

NCT04634812
COMPLETED Phase 1

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

NCT04606537
COMPLETED Phase 1

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

NCT04534699
COMPLETED Phase 1

A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects

NCT04532957
COMPLETED Phase 2

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease

NCT03574363
COMPLETED Phase 1

Bioavailability of KBP-5074 Tablet vs Capsule Formulations

NCT03340753
COMPLETED Phase 1

Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease

NCT02837237
COMPLETED Phase 1

A Multiple Ascending Dose Study of KBP-7072 in Healthy Subjects

NCT02654626
COMPLETED Phase 1

Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment

NCT02653014
COMPLETED Phase 1

Safety, Tolerability and Pharmacokinetics of KBP-7072

NCT02454361

Phase Distribution

PhaseTrial count
Phase 1 10
Phase 2 1
Phase 3 1

Therapeutic Areas

Healthy Subjects 1
Chronic Kidney Disease 1
Healthy 1

How the KBP Biosciences early-phase archive is shaped

12 indexed studies, none listed as recruiting (0% open); 11 completed (92%).

Phase mix: 1 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Healthy Subjects (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

KBP Biosciences: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

KBP Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share KBP BiosciencesAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
KBP Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

KBP Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this KBP Biosciences page

12 registered trials is a research-attention snapshot, not an endorsement of KBP Biosciences or any single study.

  • None of KBP Biosciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy Subjects is the condition KBP Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Subjects trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. KBP Biosciences pipeline card: 12 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.